Hereditary breast cancer
what we have learned in the last decade
Keywords:
hereditary breast and ovarian cancer syndrome, screening, genetic counseling, treatments, risk reductionAbstract
This literature review aims to inform and assist physicians and other health professionals in managing all information related to hereditary breast cancer, which is in constant and rapid growth, allowing for improvement in patient care and assistance. In addition, we seek to better identify which patients are eligible for the clinical criteria of association with risk of hereditary breast cancer, based on international recommendations and highlighting the main high and moderate penetrance genes that make up the multigenic panels for germline investigation in breast cancer, as well as the possibilities of clinical management that must be considered when complex decisions are required in clinical practice. Nowadays, there is more interest in population screening, in a greater supply of genetic tests, more genes included in multigene panels — allowing the search for genetic counseling —, apart from the need for clinical-decision support.
Downloads
References
Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: incidência de câncer no Brasil. Rio de Janeiro: INCA; 2019.
Global Cancer Observatory. International Agency for Research on Cancer. Available from: https://gco.iarc.fr/.
de Paula LB, Santos RS, Lima PS, de Paula NM, Reis AAS. Os genes BRCA1 e BRCA2 e suas relações genéticas na predisposição aos carcinomas mamários hereditários e esporádicos. Revista EVS-Revista de Ciências Ambientais e Saúde. 2010;37(6). http://doi.org/10.18224/est.v37i6.1898
Prolla CMD, Silva PS, Netto CBO, Goldim JR, Ashton-Prolla P. Conocimiento del cáncer de mama y cáncer de mama hereditário em el personal de enfermería de un hospital público. Rev Latino-Am Enfermagem. 2015;23(1):90-7. https://doi.org/10.1590/0104-1169.0185.2529
Ferraz VEF, Cury NM. Como o ginecologista pode orientar mulheres com antecedentes familiares de câncer? Rev Bras Ginecol Obstet. 2014;36(8):335-9. https://doi.org/10.1590/SO100-720320140005104
Corso G, Montagna G, Figueiredo J, La Vecchia C, Romario UF, Fernandes MS, et al. Hereditary gastric and breast câncer syndromes related to CDH1 germline mutation: a multidisciplinary clinical review. Cancers (Basel). 2020;12(6):1598. https://doi.org/10.3390/cancers12061598
Berliner JL, Fay AM, Cummings SA, Burnett B, Tillmanns T. NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. J Genet Couns. 2013;22(2):155-63. https://doi.org/10.1007/s10897-012-9547-1
Silva FC, Lisboa BC, Figueiredo MC, Torrezan GT, Santos EM, Krepischi AC, et al. Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients. BMC Med Genet. 2014;15:55. https://doi.org/10.1186/1471-2350-15-55
Torrezan GT, de Almeida FGSR, Figueiredo MCP, Barros BDF, de Paula CAA, Valieris R, et al. Complex landscape of germline variants in Brazilian patients with hereditary and early onset breast cancer. Front Genet. 2018;9:161. https://doi.org/10.3389/fgene.2018.00161
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: breast and ovarian. NCCN Guidelines Version 3.2019; January 18, 2019. Available from: https://www2.tri-kobe.org/nccn/guideline/gynecological/english/genetic_ familial.pdf.
Palmero EI, Alemar B, Schüler-Faccini L, Hainaut P, Moreira-Filho CA, Ewald IP, et al. Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil. Genet Mol Biol. 2016;39(2):210-22. https://doi.org/10.1590/1678-4685-GMB-2014-0363
Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117-30. https://doi.org/10.1086/375033
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66-71. https://doi.org/10.1126/science.7545954
Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265(5181):2088-90. https://doi.org/10.1126/science.8091231
Lee A, Moon BI, Kim TH. BRCA1/BRCA2 pathogenic variant breast cancer: treatment and prevention strategies. Ann Lab Med. 2020;40(2):114-21. https://doi.org/10.3343/alm.2020.40.2.114
Ashton-Prolla P, Vargas FR. Prevalence and impact of founder mutations in hereditary breast cancer in Latin America. Genet Mol Biol. 2014;37(1 suppl 1):234-40. https://doi.org/10.1590/S1415-47572014000200009
Teugels E, Brakeleer S, Goelen G, Lissens W, Sermijn E, Grève J. De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes. Hum Mutat. 2005;26(3):284. https://doi.org/10.1002/humu.9366
Peixoto A, Santos C, Rocha P, Pinheiro M, Príncipe S, Pereira D, et al. The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal. Breast Cancer Res Treat. 2009;114(1):31-8. https://doi.org/10.1007/s10549-008-9978-4
Palmero EI, Carraro DM, Alemar B, Moreira MAM, Ribeiro-Dos-Santos Â, Abe-Sandes K, et al. The germline mutational landscape of BRCA1 and BRCA2 in Brazil. Sci Rep. 2018;8(1):9188. https://doi.org/10.1038/s41598-018-27315-2
Li FP, Fraumeni Jr JF. Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann Intern Med. 1969;71(4):747-52. https://doi.org/10.7326/0003-4819-71-4-747
Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, Le Clavez-Kelm F, et al. Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat. 2010;31(2):143-50. https://doi.org/10.1002/humu.21151
Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, et al. Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed Res Int. 2015;2015:341723. https://doi.org/10.1155/2015/341723
Reis-Filho J, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378(9805):1812-23. https://doi.org/10.1016/S0140-6736(11)61539-0
Godet I, Gilkes DM. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Ther. 2017;4(1). https://doi.org/10.15761%2FICST.1000228
Coelho AS, Santos MAS, Caetano RI, Piovesan CF, Fiuza L, Machado RLD, et al. Predisposição hereditária ao câncer de mama e sua relação com os genes BRCA1 e BRCA2: revisão da literatura. RBAC. 2018;50(1):17-21. https://doi.org/10.21877/2448-3877.201800615
Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25(43):5846-53. https://doi.org/10.1038/sj.onc.1209876
Bayraktar S, Glück S. Systemic therapy options in BRCA mutation-associated breast cancer. Breast Cancer Res Treat. 2012;135(2):355-66. https://doi.org/10.1007/s10549-012-2158-6
Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015;26(7):1291-9. https://doi.org/10.1093%2Fannonc%2Fmdv022
Lee TC, Reyna C, Shaughnessy E, Lewis JD. Screening of populations at high risk for breast cancer. J Surg Oncol. 2019;120(5):820-30. https://doi.org/10.1002/jso.25611
Urban LABD, Chala LF, Bauab SP, Schaefer MB, Santos RP, Maranhão NMA, et al. Recomendações do Colégio Brasileiro de Radiologia e Diagnóstico por Imagem, da Sociedade Brasileira de Mastologia e da Federação Brasileira das Associações de Ginecologia e Obstetrícia para o rastreamento do câncer de mama. Radiol Bras. 2017;50(4):244-9. http://doi.org/10.1590/0100-3984.2017-0069
Thuler LC. Considerações sobre a prevenção do câncer de mama feminino. Rev Bras Cancerol. 2003;49(4):227-38. https://doi.org/10.32635/2176-9745.RBC.2003v49n4.2076
Pinto E, Campos R, Pinelo S, Gouveia A, Gonçalves J. Breast and gynecologic hereditary cancer. Acta Obstet Ginecol Port. 2012;6(1):20-32.
Lowry KP, Lee JM, Kong CY, McMahon PM, Gilmore ME, Chubiz JEC, et al. Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis. Cancer. 2012;118(8):2021-30. https://doi.org/10.1002/cncr.26424
Resta R, Biesecker BB, Bennett RL, Blum S, Hahn SE, Strecker MN, et al. A new definition of genetic counseling: national society of genetic counselors’ task force report. J Genet Couns. 2006;15(2):77-83. https://doi.org/10.1007/s10897-005-9014-3
Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US preventive services task force recommendation statement. JAMA. 2019;322(7):652-
https://doi.org/10.1001/jama.2019.10987
Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C, Wahlström C, et al. Breast cancer risk genes —association analysis in more than 113,000 women. N Engl J Med. 2021;384(5):428-39. https://doi.org/10.1056/NEJMoa1913948
Easton DF, Pharoah PDP, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015;372(23):2243-57. https://doi.org/10.1056/NEJMsr1501341
Freitas R, Guerra M, Fayer V, Campos A, Cintra J, Warren, J, et al. Histological and immunohistochemistry characteristics for risk of hereditary breast cancer in a cohort of Brazilian women. No prelo. 2021.
Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med. 2021;384(5):440-51. https://doi.org/10.1056/NEJMoa2005936
Narod SA. Which genes for hereditary breast cancer? N Engl J Med. 2021;384(5):471-3. https://doi.org/10.1056/NEJMe2035083
Peshkin BN, Isaacs C. Genetic testing and management of individuals at risk of hereditary breast and ovarian cancer syndromes. UpToDate. 2021. Available from: https://www. uptodate.com/contents/genetic-testing-and-management-of-individuals-at-risk-of-hereditary-breast-and-ovarian-cancer-syndromes.
Bharucha PP, Chiu KE, François FM, Scott JL, Khorjekar GR, Tirada NP. Genetic testing and screening recommendations for patients with hereditary breast cancer. Radiographics. 2020;40(4):913-36. https://doi.org/10.1148/rg.2020190181
Schon K, Tischkowitz M. Clinical implications of germline mutations in breast cancer: TP53. Breast Cancer Res Treat. 2018;167(2):417-23. https://doi.org/10.1007/s10549-017-4531-y
Evans MK, Longo DL. PALB2 mutations and breast-cancer risk. N Engl J Med. 2014;371(6):566-8. https://doi.org/10.1056/NEJMe1405784
Nielsen FC, van Overeem Hansen T, Sørensen CS. Hereditary breast and ovarian cancer: new genes in confined pathways. Nat Rev Cancer. 2016;16(9):599-612. https://doi.org/10.1038/nrc.2016.72
Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van’t Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. 2004;22(6):1055-62. https://doi.org/10.1200/JCO.2004.04.188.
Hartmann LC, Lindor NM. The role of risk-reducing surgery in hereditary breast and ovarian cancer. N Engl J Med. 2016;374(5):454-68. https://doi.org/10.1056/NEJMra1503523
Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159-64. https://doi.org/10.1056/NEJM200107193450301
Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev. 2018;4(4):CD002748. https://doi.org/10.1002/14651858.CD002748.pub4
Evans DGR, Ingham SL, Baildam A, Ross GL, Lalloo F, Buchan I, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat. 2013;140(1):135-42. https://doi.org/10.1007/s10549-013-2583-1
Heemskerk-Gerritsen BAM, Rookus MA, Aalfs CM, Ausems MGEM, Collée JM, Jansen L, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015;136(3):668-77. https://doi.org/10.1002/ijc.29032
Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348:g226. https://doi.org/10.1136/bmj.g226
van Sprundel TC, Schmidt MK, Rookus MA, Brohet R, van Asperen CJ, Rutgers EJT, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005;93(3):287-92. https://doi.org/10.1038/sj.bjc.6602703
Onitilo AA, Engel JM, Stankowski RV, Doi SAR. Survival comparisons for breast conserving surgery and mastectomy revisited: community experience and the role of radiation therapy. Clin Med Res. 2015;13(2):65-73. https://doi.org/10.3121/cmr.2014.1245
Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014;144(3):443-55. https://doi.org/10.1007/s10549-014-2890-1
Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol. 2000;18(19):3360-9. https://doi.org/10.1200/JCO.2000.18.19.3360
Pouptsis A, Swafe L, Patwardhan M, Stavraka C. Surgical and systemic treatment of hereditary breast cancer: a mini-review with a focus on BRCA1 and BRCA2 mutations. Front Oncol. 2020;10:553080. https://doi.org/10.3389/fonc.2020.553080
Nakonechny QB, Gilks CB. Ovarian cancer in hereditary cancer susceptibility syndromes. Surg Pathol Clin. 2016;9(2):189-99. https://doi.org/10.1016/j.path.2016.01.003
Kim SJ, Sota Y, Naoi Y, Honma K, Kagara N, Miyake T, et al. Determining homologous recombination deficiency scores with whole exome sequencing and their association with responses to neoadjuvant chemotherapy in breast cancer. Transl Oncol. 2021;14(2):100986. https://doi.org/10.1016/j.tranon.2020.100986
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Renata Mendes de Freitas, Pedro Medeiros, Maximiliano Ribeiro Guerra, Maria Teresa Bustamante-Teixeira
This work is licensed under a Creative Commons Attribution 4.0 International License.
